Drug Trial Radar · NCT03907488
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
994
Actual
Start
Aug 29, 2019
Primary completion
Mar 31, 2024
Study completion Mar 28, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.
Conditions
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo peripheral blood collection
Brentuximab VedotinDrug
Given IV
Computed TomographyProcedure
Undergo PET/CT or CT scan
DacarbazineDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
FilgrastimBiological
Given SC or IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
PegfilgrastimBiological
Given SC
Positron Emission TomographyProcedure
Undergo PET/CT scan
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Receive radiation therapy
Vinblastine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of registration to date of first observation of progressive disease, or death due to any cause, assessed at 2 years
Locations
728 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
Arkansas Children's Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Tower Cancer Research Foundation
Beverly Hills, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Dublin
Dublin, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Children's Hospital Los Angeles
Los Angeles, California
Showing 40 of 728 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.